Pliant Therapeutics Q1 net loss $56.2M, cuts workforce 45% to extend cash runway

PLIANT THERAPEUTICS, INC.

2025-Q1 EPS reported -$0.92

Net loss of $56.2M in Q1 2025 vs $47.0M prior-year; R&D expenses rose to $43.4M on BEACON-IPF close-out.
Announced ~45% workforce reduction on May 1, 2025, expected to be substantially completed by Q2 2025.
Cash, cash equivalents and short-term investments totaled $307.1M as of March 31, 2025.
BEACON-IPF topline data expected in Q2 2025; close-out activities ongoing.
Interim Phase 1 data for PLN-101095 plus pembrolizumab showed three confirmed partial responses in six patients at highest dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.